Get Cash Back and $0 Commissions + The Power of TradeStation
Investor Expectations to Drive Momentum within ANGI Homeservices, Aytu Bioscience, IRIDEX, Cellular Biomedicine Group, CounterPath, and EXFO Discovering Underlying Factors of Influence
Globe Newswire 16-Nov-2018 8:50 AM
NEW YORK, Nov. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ANGI Homeservices Inc. (NASDAQ:ANGI), Aytu Bioscience, Inc. (NASDAQ:AYTU), IRIDEX Corporation (NASDAQ:IRIX), Cellular Biomedicine Group, Inc. (NASDAQ:CBMG), CounterPath Corporation (NASDAQ:CPAH), and EXFO Inc (NASDAQ:EXFO), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Market Source Research, available for free download at the links above, examine ANGI Homeservices Inc. (NASDAQ:ANGI), Aytu Bioscience, Inc. (NASDAQ:AYTU), IRIDEX Corporation (NASDAQ:IRIX), Cellular Biomedicine Group, Inc. (NASDAQ:CBMG), CounterPath Corporation (NASDAQ:CPAH), and EXFO Inc (NASDAQ:EXFO) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed November 14th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
ANGI HOMESERVICES INC. (ANGI) REPORT OVERVIEW
ANGI Homeservices' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, ANGI Homeservices reported revenue of $303.12MM vs $181.72MM (up 66.81%) and analysts estimated basic earnings per share $0.06 vs -$0.17. For the twelve months ended December 31st, 2017 vs December 31st, 2016, ANGI Homeservices reported revenue of $736.39MM vs $498.89MM (up 47.60%) and analysts estimated basic earnings per share -$0.24 vs $0.03. Analysts expect earnings to be released on February 6th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.10. The estimated EPS forecast for the next fiscal year is $0.21 and is expected to report on February 6th, 2019.
For the three months ended September 30th, 2018 vs September 30th, 2017, Aytu Bioscience reported revenue of $1.43MM vs $1.08MM (up 33.02%) and analysts estimated basic earnings per share -$1.96 vs -$35.15. For the twelve months ended June 30th, 2018 vs June 30th, 2017, Aytu Bioscience reported revenue of $3.66MM vs $3.22MM (up 13.61%) and analysts estimated basic earnings per share -$15.31 vs -$48.30. Analysts expect earnings to be released on February 14th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was -$17.80. The estimated EPS forecast for the next fiscal year is -$1.09 and is expected to report on September 5th, 2019.
For the three months ended September 30th, 2018 vs September 30th, 2017, IRIDEX reported revenue of $11.32MM vs $10.87MM (up 4.19%) and analysts estimated basic earnings per share -$0.26 vs -$0.27. For the twelve months ended December 31st, 2017 vs December 31st, 2016, IRIDEX reported revenue of $41.59MM vs $46.16MM (down 9.89%) and analysts estimated basic earnings per share -$1.11 vs -$1.15. Analysts expect earnings to be released on March 14th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was -$0.44. The estimated EPS forecast for the next fiscal year is -$0.73 and is expected to report on March 14th, 2019.
For the three months ended September 30th, 2018 vs September 30th, 2017, Cellular Biomedicine Group reported revenue of $0.07MM vs $0.11MM (down 34.08%) and basic earnings per share -$0.72 vs -$0.43. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Cellular Biomedicine Group reported revenue of $0.34MM vs $0.63MM (down 46.36%) and analysts estimated basic earnings per share -$1.78 vs -$2.09. Analysts expect earnings to be released on March 5th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.48. The estimated EPS forecast for the next fiscal year is -$1.69 and is expected to report on March 5th, 2019.
For the three months ended July 31st, 2018 vs July 31st, 2017, CounterPath reported revenue of $2.89MM vs $3.11MM (down 7.23%) and analysts estimated basic earnings per share -$0.17 vs -$0.23. For the twelve months ended April 30th, 2018 vs April 30th, 2017, CounterPath reported revenue of $12.38MM vs $10.69MM (up 15.87%) and analysts estimated basic earnings per share -$0.59 vs -$0.52. Analysts expect earnings to be released on December 12th, 2018. The report will be for the fiscal period ending October 31st, 2018.
For the three months ended May 31st, 2018 vs May 31st, 2017, EXFO reported revenue of $72.22MM vs $58.51MM (up 23.44%) and analysts estimated basic earnings per share -$0.11 vs -$0.08. For the twelve months ended August 31st, 2018 vs August 31st, 2017, EXFO reported revenue of $269.55MM vs $243.30MM (up 10.79%) and analysts estimated basic earnings per share -$0.22 vs $0.02. Analysts expect earnings to be released on January 8th, 2019. The report will be for the fiscal period ending November 30th, 2018. The reported EPS for the same quarter last year was $0.06. The estimated EPS forecast for the next fiscal year is $0.14 and is expected to report on October 10th, 2019.
Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.
REGISTERED MEMBER STATUS
Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at compliance@MarketSourceResearch.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
